NASDAQ:ERNA Ernexa Therapeutics Q2 2026 Earnings Results & Report $2.40 -0.09 (-3.61%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$2.35 -0.05 (-2.25%) As of 10/9/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Ernexa Therapeutics missed analyst earnings expectations in its Q2 2026 results, released August 6, 2026. The company reported EPS of -$3.40 versus the -$3.30 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 6, 2026TimeBefore Market Opens Ernexa Therapeutics EPS ResultsActual EPS-$3.40Consensus EPS -$3.30Beat/MissMissed by -$0.10One Year Ago EPSN/AErnexa Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsErnexa Therapeutics' next earnings date is estimated for Friday, November 6, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Ernexa Therapeutics Q2 2026 Earnings FAQ Did Ernexa Therapeutics beat earnings estimates for Q2 2026? Ernexa Therapeutics (NASDAQ:ERNA) reported earnings of -$3.40 per share for Q2 2026, missing the consensus estimate of -$3.30. The report was announced on Thursday, August 6, 2026. When is Ernexa Therapeutics' next earnings date? Ernexa Therapeutics' next earnings date is estimated for Friday, November 6, 2026. MarketBeat tracks confirmed and estimated earnings dates for Ernexa Therapeutics on the company's earnings history page. Ernexa Therapeutics Earnings HeadlinesAutolus Therapeutics (NASDAQ:AUTL) vs. Ernexa Therapeutics (NASDAQ:ERNA) Financial ComparisonOctober 8 at 4:59 AM | americanbankingnews.comErnexa Therapeutics Announces ERNA-101 Preclinical Data Selected For Flash Talk Presentation At Nature Conferences? Next-Generation Cancer Therapeutics Meeting Co-Hosted By MD ...October 7 at 11:23 PM | marketscreener.comMAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly 80% afterward. He also called the housing crisis and the collapse of Bear Stearns and Lehman Brothers before they happened. Now Tilson says the day after this year's midterm elections, America enters a period of economic change unlike anything seen in decades - and most investors are unprepared. | Stansberry Research (Ad)Relay Therapeutics (NASDAQ:RLAY) and Ernexa Therapeutics (NASDAQ:ERNA) Head-To-Head AnalysisOctober 7 at 5:14 AM | americanbankingnews.comErnexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer CenterOctober 6, 2026 | finance.yahoo.comErnexa Therapeutics' ERNA-101 Selected for Flash Talk Presentation at Nature Conferences' Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer CenterOctober 6, 2026 | globenewswire.comSee More Ernexa Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ernexa Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ernexa Therapeutics and other key companies, straight to your email. Email Address About Ernexa TherapeuticsEterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.View Ernexa Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
